Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of CTH120 in Healthy Volunteers
NCT06480968Phase 1Completed
- Sponsor
- CONNECTA Therapeutics
- Start
- Jun 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CTH120 in Fragile X syndrome (FXS) (5 arms), sponsored by CONNECTA Therapeutics. Primary endpoints: Treatment-emergent adverse events, Treatment-emergent potentially clinically significant abnormalities in blood pressure and 9 more. Started Jun 2023; status: completed.
02
Drugs
CTH120
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT06480968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06480968.